

A Study to Evaluate COR-1004 in Adult Volunteers.

NCT07229118

Status	RECRUITING
Phase	Phase 1
Sponsor	Corsera Health
Enrollment	60 participants

Key Eligibility Criteria

Inclusion (5)

- Serum LDL-C \leq 100 mg/dL (\leq 2.6 mmol/L) at Screening.
- Female participants who are of childbearing potential must be willing to use two highly effective methods of contraception, one of which should be a barrier method.
- Post-menopausal females must be post-menopausal for 12 months.
- Male participants and their partners of child-bearing potential, or same-sex partners, must be willing to use two highly effective methods of contraception, one of which must be a barrier method (eg, condom) for 90 days after study drug administration.
- Able to participate, and willing to give written informed consent and to comply with the study restrictions.

Exclusion (18)

- Any active or chronic disease.
- Active or history of serious mental illness or psychiatric disorder.
- Clinically significant illness within seven days before study drug administration.
- Having risk of atherosclerotic cardiovascular disease (ASCVD) \geq 7.5% based on the ASCVD Risk Estimator Plus.
- Having fasting triglyceride level \geq 400 mg/dL (\geq 4.52 mmol/L).

... and 13 more (see full listing online)

Locations (1 total)

Clinical Trial Site, Christchurch, New Zealand